within Pharmacolibrary.Drugs.ATC.V;

model V09DB01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09DB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Technetium (99mTc) nanocolloid is a radiopharmaceutical agent used primarily for lymphoscintigraphy, sentinel lymph node mapping, and imaging of the reticuloendothelial system (liver, spleen, bone marrow). It is approved for clinical use in nuclear medicine imaging and is administered typically via subcutaneous or intravenous injection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters (central compartment distribution and clearance) are estimated based on known radiocolloid PK in adult humans. Nanocolloid particles remain mostly at the injection site, are taken up by lymphatics or phagocytosed by the reticuloendothelial system. Only a small proportion reaches systemic circulation. Model assumes intravenous route for parameter estimation, adults.</p><h4>References</h4><ol><li><p>Oyen, WJ, et al., &amp; Corstens, FH (1996). Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 37(8) 1392–1397. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8708782/\">https://pubmed.ncbi.nlm.nih.gov/8708782</a></p></li><li><p>Tishler, M, et al., &amp; Golan, H (2010). 99m Tc-albumin nanocolloid joint scintigraphy in rheumatoid arthritis patients who are in clinical remission - is remission real ?. <i>Clinical and experimental rheumatology</i> 28(3) 360–364. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20426913/\">https://pubmed.ncbi.nlm.nih.gov/20426913</a></p></li><li><p>Alkandari, AM, et al., &amp; Alsayed, YM (2020). Preclinical Assessment of . <i>Journal of nuclear medicine technology</i> 48(3) 269–273. DOI:<a href=\"https://doi.org/10.2967/jnmt.119.239756\">10.2967/jnmt.119.239756</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32518123/\">https://pubmed.ncbi.nlm.nih.gov/32518123</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09DB01;
